REG - EKF Diagnostics Hldg - Non-executive Directorate Change

EKF Diagnostics HoldingsAnnouncement

31/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220131:nRSe0562Aa&default-theme=true

RNS Number : 0562A  EKF Diagnostics Holdings PLC  31 January 2022

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Non-executive Directorate Change

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care
business, announces the appointment of Jenny Winter as Non-executive Director
("NED"), effective on 1 February 2022. At the same time Carl Contadini,
Non-executive Director, will stand down from the Board.

 

Jenny has over 20 years' experience across a broad variety of healthcare
organisations ranging from small not-for-profit companies to large corporates.
Jenny is currently Chief Executive Officer of AIM listed Animalcare Group plc
(AIM: ANCR) where she is successfully executing on the business's long-term
growth strategy, as reflected in the recently announced strong full year
trading performance against a backdrop of very challenging market conditions.

 

Jenny has a science-led career spanning R&D, clinical research, strategic
product development and commercial growth across various aspects of the
healthcare industry. Before joining Animalcare Group plc in October 2018,
Jenny was Vice President of Respiratory products - Global Supply Chain and
Strategy at AstraZeneca, a position she held from 2015. Other roles at
AstraZeneca included Vice President Cardiology - Global Product and Portfolio
Strategy, Commercial Director - Eastern Europe, Marketing Company President
Hungary, where she led a major change programme to drive future success, and
Global Vice President, Group Public Affairs.

 

Jenny has also been CEO of the charity Barretstown, transforming it into a
successful leading charity  which provides therapeutic recreation programmes
for children and their families affected by serious illness, as well as
virtual school and hospital outreach activities. Her work at the charity
resulted in her being invited by Barretstown board member Dermot Gleeson,
Chairman of Allied Irish Bank, to join the Board of the bank as a
Non-executive Director, a role she held from 2004 to 2010.

 

Jenny has a BSc in Physiology and Pharmacology from the University of
Southampton.

 

Christopher Mills, Chairman of EKF, commented:

 

"I would like to thank Carl for his valuable contribution to the Board over
the last five-and-a-half years. Carl has provided sound guidance to the
Executive and operational teams as they've executed a successful growth
strategy, reflected in the positive trading update and upgraded year-end
guidance provided last week.

 

"We are also delighted to welcome Jenny to the Board. I have no doubt that
Jenny will bring a lot to the table in terms of her scientific background,
commercial knowledge within the healthcare sector and her experience with AIM
listed companies as they successfully deliver against long-term growth
strategies. We look forward to working with her and benefitting from her
expertise."

 

Additional disclosures relating the appointment of Jenny Winter to the EKF
Board are included below.

 

 EKF Diagnostics Holdings plc                                  www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Christopher Mills, Non-Executive Chairman                      Tel: +44 (0)29 2071 0570
 Mike Salter, CEO
 Marc Davies, CFO

 Singer Capital Markets (Nominated Adviser & Joint Broker)                                   Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas / Tom Salvesen

 Investec Bank plc (Joint Broker)                              Tel: +44 (0)20 7597 4000
 Gary Clarence / Daniel Adams / Ben Farrow

 Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

EKF is a leading point-of-care diagnostics and central laboratory assay
manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose
and lactate analysers in regular use across more than 100 countries. EKF
specialises in developing tests for use in anemia and diabetes diagnosis and
management, as well as providing a portfolio of reagents for use in clinical
chemistry analysers.

 

EKF specialises in the development, production and worldwide distribution of
point-of-care analyzers and clinical chemistry reagents for use in hospital
and research laboratories, doctor's offices, blood banks and for in-field
anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and
has custom manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. Driven by customer demand EKF has invested
significantly in increasing the Company's fermentation capacity. The Company's
capabilities and capacity in contract manufacturing for sample collection,
tests and test kits have seen dramatic growth following strong demand for
during the COVID-19 pandemic, and these income streams are now being
diversified for application to other non-COVID areas of diagnostic testing,
molecular disease and forensic test manufacture.

 

In May 2021, EKF outlined its strategy through to 2024 for delivering
additional growth. As well as the growth expected in Contract Manufacturing
across Life Sciences, molecular diagnostics and other applications, the
Company expects to leverage existing distribution channels for organic growth,
both in the core business and from additional products to expand the core
range, but also through executing earnings enhancing acquisitions and
delivering further value creating investments associated with the preferred
partnership agreement with Mount Sinai Innovation Partners.

 

In October 2021, EKF completed the acquisition of Advanced Diagnostic
Laboratory LLC, a Texas based testing laboratory certified under the Clinical
Laboratory Improvement Amendments ("CLIA") for high complexity testing. The
laboratory provides testing for a variety of clinical, forensic and
microbiological sample types using a range of analytical techniques. This
acquisition positions EKF as a leading 'one stop' provider of diagnostic
products and services from sample collection to results.

 

Additional Disclosures Required under the AIM Rules for Companies

 

Jennifer Ann Julia Winter (aged 62) has held the following directorship or
partnerships in the past five years:

 

Current directorships and partnerships:

 

Animalcare Group PLC

Animalcare Ltd (subsidiary of Animalcare Group PLC)

Identicare Ltd (subsidiary of Animalcare Group PLC)

 

Previous directorships and partnerships held in the past five years:

 

Oxford Genetics Ltd

 

Jenny does not hold any ordinary shares in EKF.

 

Save as disclosed above, there is no further information to be disclosed in
respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph
(g) of the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASEAFFUEESELF